André L. Lamotte
Oprichter bij Acambis Plc
Profiel
André L.
Lamotte was the founder of Inspire Pharmaceuticals, Inc. (founded in 1993), Ligand UK Ltd.
(founded in 1988), Neusentis, Inc. (founded in 1992), Medical Science Partners LP (founded in 1988), and New Medical Technologies AG (founded in 2003).
He is also the founder of Laser Vision Centers, Inc., Acambis Plc, CryoCath Technologies, Inc., Creagen, Inc., Axovan AG, Diatide, Inc., URRMA Biopharma, Inc., and Evolva Holding SA. Currently, Dr. Lamotte is the Director & Co-Owner of Medical Specialty Products International AG.
In the past, he held positions such as Chairman at Arpida AG (1997-2009), Director at Agenix Ltd., URRMA Biopharma, Inc., and Urma AG, Investment Advisor at HBM Partners AG (2004-2006), and Vice President & General Partner at Pasteur Merieux, Inc. (1983-1988).
Dr. Lamotte holds an MBA from Harvard University and a doctorate from the Massachusetts Institute of Technology.
Actieve functies van André L. Lamotte
Bedrijven | Functie | Begin |
---|---|---|
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Oprichter | 15-12-2009 |
URRMA Biopharma, Inc. | Oprichter | 15-12-2009 |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Oprichter | 15-12-2009 |
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Oprichter | 15-12-2009 |
Creagen, Inc.
Creagen, Inc. Pharmaceuticals: OtherHealth Technology Part of Perrigo Co. Plc, Creagen, Inc. is a biopharmaceutical development company. The company is based in Cambridge, MA. The company was founded by André L. Lamotte, Roberto Crea. Creagen was acquired by Neurex Corp. on July 26, 1994 for $8.05 million. | Oprichter | 15-12-2009 |
Diatide, Inc.
Diatide, Inc. Pharmaceuticals: GenericHealth Technology Diatide, Inc. is a company based in Londonderry, NH. Diatide, Inc. was founded by André L. Lamotte. | Oprichter | 15-12-2009 |
Medical Specialty Products International AG | Directeur/Bestuurslid | 19-04-2011 |
Eerdere bekende functies van André L. Lamotte
Bedrijven | Functie | Einde |
---|---|---|
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | Voorzitter | 14-12-2009 |
Laser Vision Centers, Inc.
Laser Vision Centers, Inc. Finance/Rental/LeasingFinance Laser Vision Centers, Inc.. provides a broad range of initial training of physicians and staff, technical support and equipment maintenance, marketing, clinical advisory service, patient financing, partnership opportunities, and practice satelliting. | Oprichter | 13-06-2009 |
░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van André L. Lamotte
Harvard University | Masters Business Admin |
Massachusetts Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
EVOLVA HOLDING SA | Consumer Non-Durables |
Bedrijven in privébezit | 18 |
---|---|
Laser Vision Centers, Inc.
Laser Vision Centers, Inc. Finance/Rental/LeasingFinance Laser Vision Centers, Inc.. provides a broad range of initial training of physicians and staff, technical support and equipment maintenance, marketing, clinical advisory service, patient financing, partnership opportunities, and practice satelliting. | Finance |
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Health Technology |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
CryoCath Technologies, Inc.
CryoCath Technologies, Inc. Medical SpecialtiesHealth Technology CryoCath Technologies, Inc. manufactures medical equipment. The company was founded by Normand Balthazard and Andre L. Lamotte in 1994 and is headquartered in Montreal, QC. | Health Technology |
Agenix Ltd.
Agenix Ltd. Packaged SoftwareTechnology Services Agenix Ltd. is an international biotechnology company with a wholly-owned subsidiary in China. It develops and researches medical diagnostic products. Agenix was founded on January 15, 1987 and is headquartered in Melbourne, Australia. | Technology Services |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Health Technology |
Medical Science Partners LP
Medical Science Partners LP Investment ManagersFinance Profile unavailable. | Finance |
Creagen, Inc.
Creagen, Inc. Pharmaceuticals: OtherHealth Technology Part of Perrigo Co. Plc, Creagen, Inc. is a biopharmaceutical development company. The company is based in Cambridge, MA. The company was founded by André L. Lamotte, Roberto Crea. Creagen was acquired by Neurex Corp. on July 26, 1994 for $8.05 million. | Health Technology |
New Medical Technologies AG | Finance |
Axovan AG
Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
Arpida AG
Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | Health Technology |
Diatide, Inc.
Diatide, Inc. Pharmaceuticals: GenericHealth Technology Diatide, Inc. is a company based in Londonderry, NH. Diatide, Inc. was founded by André L. Lamotte. | Health Technology |
Pasteur Merieux, Inc. | |
URRMA Biopharma, Inc. | |
Urma AG | |
Medical Specialty Products International AG |